Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $117 from $125 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results and although frustrated, are sticking with the name.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH: